Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05091528
Title A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Silverback Therapeutics

breast cancer

lung non-small cell carcinoma

stomach cancer

colorectal cancer

Advanced Solid Tumor


SBT6050 + Trastuzumab deruxtecan

SBT6050 + Trastuzumab + Tucatinib

Capecitabine + SBT6050 + Trastuzumab + Tucatinib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.